Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluorouracil + irinotecan liposome + leucovorin calcium + rucaparib
- Development stage
- Unknown
- Lead developer
- Academic and Community Cancer Research United
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
A combination therapy consisting of fluorouracil (5-FU), liposomal irinotecan (nal-IRI), leucovorin calcium (LV), and rucaparib. This regimen combines traditional chemotherapy agents with a PARP inhibitor. The chemotherapy components (liposomal irinotecan, fluorouracil, and leucovorin calcium) work in different ways to stop tumor cell growth by killing cells, stopping cell division, or preventing cell spread. Rucaparib, a PARP inhibitor, prevents cancer cells from repairing DNA damage, potentially enhancing the cytotoxic effects of the chemotherapy agents. Preclinical evidence suggests synergistic antitumor effects between topoisomerase inhibitors (like irinotecan) and PARP inhibitors (like rucaparib).
02
Targets
PARP3 (Poly(adp-ribose) polymerase 3)TOP1 (DNA Topoisomerase I)TS (Thymidylate synthase)PARP2 (Poly (adp-ribose) polymerase 2)
Beyond the preview
Go deeper on fluorouracil + irinotecan liposome + leucovorin calcium + rucaparib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluorouracil + irinotecan liposome + leucovorin calcium + rucaparib.